Shanghai Henlius Biotech, Inc. (2696.HK) announced that its self-developed innovative anti-PD-1 monoclonal antibody HANSIZHUANG (serplulimab, Hetronifly® in Europe), in combination with chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback